MedPath

A randomized comparative study of Celecoxib and Limaprost alfadex on the patients with lumber spinal stenosis for the effectiveness for symptoms and QO

Phase 3
Conditions
umbar spinal stenosis
Registration Number
JPRN-UMIN000004825
Lead Sponsor
niversity of Tsukuba, Course of life-style related disorders donated by JA Ibaraki Public Welfare Federation
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
134
Inclusion Criteria

Not provided

Exclusion Criteria

1.Congenital lumbar spinal stenosis 2.Operation for lumbar spinal stenosis before three months 3.Indication for operation 4.Taking NSAIDs, Limaprost and Steroids before a week 5.Exclusion criteria a)ASO and below 0.9 of ABI b)Cerebral infarction c)Gait disturbance with Knee and hip osteoarthritis d)Diabetes (HbA1c>10% or diabetic neuropathy) 6. Severe low back pain and vertebral body fracture 7. Severe systemic past history such as heart, liver or kidney disease 8. Peptic ulcer 9. Severe abnormal symptom of blood 10. Pregnant or intend to become pregnant during the study period 11. History of hypersensitivity to Limaprost, celecoxib and sulfonamide 12. Aspirin-induced asthma 13. Patients who were recognized unsuitable for this study by primary physician

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Zurich claudication questionnaire
Secondary Outcome Measures
NameTimeMethod
6-minute walk test JOA back pain evaluation questionnaire SF-36 Lumber extension test Safety: adverse events
© Copyright 2025. All Rights Reserved by MedPath